Hemophilia B
from OrphaChat — a Rare Disease Podcast Hosted by RCH
These sources provide a comprehensive overview of the clinical management and evolving treatment landscape for hemophilia, with a specific focus on hemophilia B. They detail traditional factor replacement therapies, the use of extended half-life products, and the emergence of novel non-factor agents like emicizumab and fitusiran. Significant emphasis is placed on long-term gene therapy data, specifically for etranacogene dezaparvovec, which has demonstrated the potential to sustain normal clotting levels and eliminate the need for regular infusions over five years. The texts also address critical safety complications, such as the development of neutralizing inhibitors and the risk of anaphylactic reactions during treatment. Beyond clinical care, the documentation outlines essential administrative protocols, including CPT billing codes for chronic care management and HCPCS codes for specific medicinal injections. Finally, global best practices and guidelines are highlighted to standardise care, emphasizing the importance of specialised treatment centres and accurate diagnostic laboratory testing.
Embed this episode
No transcript yet.